|
Vista Partners gibt für Raptor ein 12-Monatskursziel von 5,55 US-Dollar aus. Am Markt wird dies kaum zur Kenntnis genommen. Originalmeldung: LOS ANGELES, Feb 11, 2010 /PRNewswire via COMTEX/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceutical Corp. and raised its split adjusted twelve month target price to $5.55. Ross Silver, Principal Analyst for Vista Partners stated, "Raptor's current valuation is well below its peer group which does not make a lot of sense considering Raptor is currently involved in five Phase II clinical programs with some indications in multi-billion dollar markets. The recently closed $7.5M equity offering will enable the Company to move all of their principal clinical programs forward, with a primary focus on their lead compound, DR Cysteamine, for the treatment of cystinosis." Mr. Silver continued, "With a strong balance sheet, robust clinical pipeline and management team that has taken compounds from concept to approval twice already, we believe Raptor should trade at a premium to their peer group and as such we anticipate significant share price appreciation in 2010." For more information and to download the report for FREE, please visit the Vista Partners website at www.vistap.com and click on the "download research" icon or click here. |
|
| aus der Diskussion: | RPTP = Top Management und Krass Unterbewertet !!! |
| Autor (Datum des Eintrages): | fernandopessoa (12.02.10 12:57:43) |
| Beitrag: | 25 von 48 (ID:38933668) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |